QBiotics has announced the appointment of Sergio Duchini to its board as a non-executive director, effective today (1 July).
QBiotics is an unlisted, public, Australian life sciences company. Its current focus is on novel treatments for cancer and debilitating chronic wounds. The company's lead molecule, tigilanol tiglate, is currently in Phase 2 clinical trials for two indications: soft tissue sarcoma and head and neck cancer.
Mr Duchini brings more than 30 years of executive and board-level experience across biotechnology, healthcare, technology, and professional services. He currently serves as non-executive chair of Neurizon Therapeutics, a clinical-stage company advancing NUZ-001 for amyotrophic lateral sclerosis and other neurodegenerative diseases. He is also a non-executive director and chair of the Audit and Risk Committee for Enlitic, an AI-driven medical imaging business.
He has also served as chair of Lymphoma Australia, non-executive director of AusBiotech, and a former board member of Deloitte Australia. He also has over 30 years of professional services experience, including 23 years as a Deloitte Tax Partner. During his tenure at Deloitte, he advised on innovation strategy, R&D investments, and M&A, and played a key role in the integration of Deloitte Asia Pacific.
QBiotics chair, Mark Fladrich, said, “On behalf of my fellow directors, we are delighted to welcome Sergio to the Board of QBiotics. His deep experience across biotechnology, healthcare and professional services, combined with his proven governance and strategic insights will be invaluable in supporting our clinical and commercial progress.”
Mr Duchini added, “I’m delighted to be joining the Board of QBiotics at this important stage in its history. I have long admired QBiotics’ pioneering science and have been impressed by the strength of its innovation platform, translational capability, and commitment to delivering real-world impact. I look forward to contributing to QBiotics’ continued growth and global aspirations.”